Press release
Melanoma Cancer Diagnostics Market Report on Future Trends Analysis and Growth Opportunity to Surpass US$ 853.5 Million in Revenues by 2022: Melanoma Cancer Diagnostics Market Taxonomy Test Type (BRAF Mutation, CTC, Immunohistochemistry, In Situ Hybridiza
To Understand the Melanoma Cancer Diagnostics Market Industry Status worldwide, MRRSE has included the latest Forecast report titled “Melanoma Cancer Diagnostics Market Report on Future Trends Analysis and Growth Opportunity to Surpass US$ 853.5 Million in Revenues by 2022: Melanoma Cancer Diagnostics Market Taxonomy Test Type (BRAF Mutation, CTC, Immunohistochemistry, In Situ Hybridization and Others.)”, to its vast database. This study offers data about the prime regions operating in the Melanoma Cancer Diagnostics Market, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR until 2022.Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for melanoma cancer. Rising number of deaths caused by melanoma cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of melanoma cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of melanoma cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.
Get Free Sample Report Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=57
Melanoma or malignant melanoma is a common type of skin cancer where melanocytes, cells containing pigments, begin to grow rapidly. Since occurrence of melanoma is restricted to skin, mouth, intestines or eyes, the diagnostics of melanoma comprises of multiple tests & screening methods such as excisional biopsy, lymph node status analysis, shave biopsy, and fine needle aspirate test.
The global melanoma cancer diagnostics market is projected to grow at a steady CAGR during the forecast period 2017-2027. The melanoma cancer diagnostics market will be influenced by a combination of macroeconomic and microeconomic factors. Increasing spending on healthcare and advances in cancer detection and management are expected to contribute to the growth of the melanoma cancer diagnostics market. However, dearth of advanced solutions in developing countries will continue to pose growth challenges.
By test type, the BRAF mutation test type segment will continue to be used widely for detecting the early onset of melanoma. In terms of revenue share, North America will account for majority share of revenues for the BRAF mutation segment globally. Use of BRAF mutation test type will also remain prevalent in Europe and APEJ.
The CTC segment will grow at a higher CAGR than BRAF mutation test type, with North America holding largest market share. However, it is the APEJ market where revenues will grow at the highest pace.
The immunohistochemistry segment of the global melanoma market is valued at over US$ 80 million in 2017. North America will remain the largest market for immunohistochemistry, followed by Europe and APEJ. Overall, the immunohistochemistry segment is projected to grow at a significant CAGR through 2022.
Browse Complete Report In-Depth Here - https://www.factmr.com/report/57/melanoma-cancer-diagnostics-market
North America will remain an attractive market for global melanoma cancer diagnostic market. As discussed previously, BRAF mutation will remain the most widely used test type, followed by CTC. Hospital associated labs will continue to be the largest end-users in the North America melanoma cancer diagnostics market.
Europe, the second-largest market for melanoma cancer diagnostics, will continue to offer growth opportunities to manufacturers. By test type, the CTC cancer diagnostics market will continue to grow at highest CAGR, whereas hospital associated labs will be the largest end-users.
Overall, North America and Europe will continue to be the two most lucrative markets for melanoma cancer diagnostics globally.
Competition Tracking
The key companies profiled in the FactMR’s report on global melanoma cancer diagnostics market include Foundation Medicine, Inc., Cancer Genetics, Inc., Pathway Genomics Corporation, Abbott Laboratories, and Myriad Genetics Inc.
Table of Contents
Chapter 1. Global Melanoma Cancer Diagnostics Market - Executive Summary. 20
Chapter 2. Global Melanoma Cancer Diagnostics Market Overview. 22
2.1. Introduction. 22
2.1.1. Global Melanoma Cancer Diagnostics Market Taxonomy. 22
2.1.2. Global Melanoma Cancer Diagnostics Market Definition. 22
2.2. Global Melanoma Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 22
2.2.1. Global Melanoma Cancer Diagnostics Market Y-o-Y Growth. 22
2.3. Global Melanoma Cancer Diagnostics Market Dynamics. 23
2.3.1. Drivers. 23
2.3.2. Restraints. 23
2.3.3. Trends. 23
2.4. Supply Chain. 24
2.5. Epidemiology. 24
2.6. List of Distributors. 24
2.7. Average Pricing Analysis. 24
2.8. Regulations. 25
2.9. Key Participants Market Presence (Intensity Map) By Region. 25
Chapter 3. Global Melanoma Cancer Diagnostics Market Analysis and Forecast By Test Type. 26
3.1. Global Melanoma Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 26
3.1.1. BRAF Mutation Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 26
3.1.1.2. Market Share Comparison, By Region. 28
Continued……………………………..
Buy This Report from Here - https://www.factmr.com/checkout/57/S
About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Sports market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us -
FactMR
Suite 9884
27 Upper Pembroke Street, Dublin 2, Ireland
Telephone @ +353-1-6111-593
Email: sales@factmr.com
Website: https://www.factmr.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Melanoma Cancer Diagnostics Market Report on Future Trends Analysis and Growth Opportunity to Surpass US$ 853.5 Million in Revenues by 2022: Melanoma Cancer Diagnostics Market Taxonomy Test Type (BRAF Mutation, CTC, Immunohistochemistry, In Situ Hybridiza here
News-ID: 1137607 • Views: …
More Releases from Fact.MR

Bioinformatics Market is Growing at a CAGR of 13.4% by 2034 | Fact.MR Report
The latest report on the Bioinformatics Market, projecting robust growth driven by the increasing demand for genomic research, advancements in artificial intelligence (AI), and the rising adoption of precision medicine. Valued at USD 14.29 billion in 2024, the global market is forecast to expand at a compound annual growth rate (CAGR) of 13.4%, reaching USD 50.25 billion by 2034. This significant growth underscores the critical role of bioinformatics in decoding…

Residential Robotic Vacuum Cleaner Market to Reach USD 11.6 Billion by 2033 | Ke …
Fact.MR today released its latest report on the Residential Robotic Vacuum Cleaner Market, projecting robust growth driven by increasing demand for automation, busy lifestyles, and advancements in smart home technologies. Valued at USD 3.0 billion in 2023, the global market is forecast to expand at a compound annual growth rate (CAGR) of 14.4%, reaching USD 11.6 billion by 2033. This significant growth highlights the rising adoption of robotic vacuum cleaners…

Brain-Computer Interface Market is Estimated to Reach USD 6.5 Billion by 2033
The global brain-computer interface (BCI) market was valued at USD 1.6 billion in 2022 and is projected to reach USD 6.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.6% from 2023 to 2033. This expansion reflects the increasing adoption of BCI technologies in medical applications, driven by advancements in neuroscience, AI, and sensor technologies. BCIs enable direct communication between the brain and external devices, offering…

Orally Disintegrating Tablet Market is Projected to Reach USD 72.68 Billion by 2 …
The global orally disintegrating tablet (ODT) market is valued at USD 24.45 billion in 2024 and is forecasted to expand at a compound annual growth rate (CAGR) of 11.5%, reaching USD 72.68 billion by 2034. This robust growth is driven by the increasing demand for patient-friendly dosage forms, particularly among the elderly, pediatric, and dysphagic populations, who benefit from ODTs' ease of administration without water and rapid dissolution. ODTs enhance…
More Releases for Melanoma
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period?
The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment…
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market?
The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt…
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market?
The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in…
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Qiagen NV
• Sun Pharmaceutical Industries Ltd…
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…